These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12941314)

  • 21. Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
    Yang TH; Lee CI; Huang WH; Lee AR
    Molecules; 2017 May; 22(6):. PubMed ID: 28561780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
    Boyer SJ
    Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the α
    Sartori A; Portioli E; Battistini L; Calorini L; Pupi A; Vacondio F; Arosio D; Bianchini F; Zanardi F
    J Med Chem; 2017 Jan; 60(1):248-262. PubMed ID: 27997164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
    Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
    J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
    Bold G; Altmann KH; Frei J; Lang M; Manley PW; Traxler P; Wietfeld B; Brüggen J; Buchdunger E; Cozens R; Ferrari S; Furet P; Hofmann F; Martiny-Baron G; Mestan J; Rösel J; Sills M; Stover D; Acemoglu F; Boss E; Emmenegger R; Lässer L; Masso E; Roth R; Schlachter C; Vetterli W
    J Med Chem; 2000 Jun; 43(12):2310-23. PubMed ID: 10882357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.
    Bold G; Schnell C; Furet P; McSheehy P; Brüggen J; Mestan J; Manley PW; Drückes P; Burglin M; Dürler U; Loretan J; Reuter R; Wartmann M; Theuer A; Bauer-Probst B; Martiny-Baron G; Allegrini P; Goepfert A; Wood J; Littlewood-Evans A
    J Med Chem; 2016 Jan; 59(1):132-46. PubMed ID: 26629594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
    Harris PA; Cheung M; Hunter RN; Brown ML; Veal JM; Nolte RT; Wang L; Liu W; Crosby RM; Johnson JH; Epperly AH; Kumar R; Luttrell DK; Stafford JA
    J Med Chem; 2005 Mar; 48(5):1610-9. PubMed ID: 15743202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.
    Bilodeau MT; Cunningham AM; Koester TJ; Ciecko PA; Coll KE; Huckle WR; Hungate RW; Kendall RL; McFall RC; Mao X; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2485-8. PubMed ID: 12852948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
    Maskell L; Blanche EA; Colucci MA; Whatmore JL; Moody CJ
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1575-8. PubMed ID: 17254788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
    Kirk NS; Bezos A; Willis AC; Sudta P; Suksamrarn S; Parish CR; Ranson M; Kelso MJ
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1813-6. PubMed ID: 26912111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
    Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Property-based design of KDR kinase inhibitors.
    Fraley ME; Hoffman WF; Arrington KL; Hungate RW; Hartman GD; McFall RC; Coll KE; Rickert K; Thomas KA; McGaughey GB
    Curr Med Chem; 2004 Mar; 11(6):709-19. PubMed ID: 15032725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
    Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.
    Lézé MP; Le Borgne M; Pinson P; Palusczak A; Duflos M; Le Baut G; Hartmann RW
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1134-7. PubMed ID: 16380254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.
    Choquette D; Teffera Y; Polverino A; Harmange JC
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4054-8. PubMed ID: 18573658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.